A Phase 1 interventional study of Co-administration of DWC20155/DWC20156 and DWC20162 in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-16.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 196 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
To study effect of DWC20162 on DWC20155/DWC20156 PK
Drug: Co-administration of DWC20155/DWC20156 · Drug: DWC20162
To study effect of DWC20155/DWC20156 on DWC20162 PK
Drug: Co-administration of DWC20155/DWC20156 · Drug: DWC20162
Maximum Plasma Concentration (Cmax)
Time frame: 0 ~ 24 hours
Area under the time versus plasma concentration curve (AUC)
Time frame: 0 ~ 24 hours
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD.